250 results on '"Saunthararajah Y"'
Search Results
2. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron
3. Critical Updates to the Leukemia Stem Cell Model
4. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
5. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
6. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors
7. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
8. p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
9. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies
10. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
11. Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation
12. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma
13. S135 NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS
14. Chapter 4 - Critical Updates to the Leukemia Stem Cell Model
15. The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)
16. 310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES
17. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
18. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron
19. Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation
20. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
21. Differences in Iron Distribution in Patients with Myelodysplastic Syndromes Carrying SF3B1 Mutations Using Energy-dispersive X-ray Spectroscopy (XEDS) and Electron-Energy Loss Spectroscopy (EELS)
22. P-010 Distinct methylation signature in MDS patients with SF3B1 mutations confers a novel mechanism of disease pathogenesis
23. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
24. The relationship of cigarette smoking to invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy (IC).
25. Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8 abnormalities.
26. 230: Fludarabine/full dose I.V. busulfan conditioning regimen in allogeneic PBSC transplantation for high risk patients
27. Pretransplant recipient blood CD14+ preDC levels correlate with increased acute GVHD after allogeneic PBSC transplantation
28. Can we consider fludarabine/ full dose I.V. busulfan a reduced intensity conditioning regimen?
29. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process
30. The Similarity of Class II HLA Genotypes Defines Patterns of Autoreactivity in Idiopathic Bone Marrow Failure Disorders
31. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
32. S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis).
33. Promising Therapy for Bone Marrow Failure from Myelodysplastic Syndromes.
34. A 68-year-old man with thrombocytosis and ringed sideroblasts.
35. Higher Numbers of Blood CD14+ Cells before Starting Conditioning Regimen Correlate with Greater Risk of Acute Graft-versus-Host Disease in Allogeneic Stem Cell Transplantation from Related Donors
36. Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation
37. Oncotherapy resistance explained by Darwinian and Lamarckian models.
38. Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.
39. Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.
40. Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy.
41. Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF.
42. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.
43. DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway.
44. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
45. Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.
46. Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia.
47. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
48. Functional characterization of NPM1-TYK2 fusion oncogene.
49. The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.
50. Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.